Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?

Cara A. Timpani, Kamel Mamchaoui, Gillian Butler-Browne, Emma Rybalka
2020 Antioxidants  
The discordance between pre-clinical success and clinical failure of treatment options for Duchenne Muscular Dystrophy (DMD) is significant. The termination of clinical trials investigating the phosphodiesterase inhibitors, sildenafil and tadalafil (which prolong the second messenger molecule of nitric oxide (NO) signaling), are prime examples of this. Both attenuated key dystrophic features in the mdx mouse model of DMD yet failed to modulate primary outcomes in clinical settings. We have
more » ... ously attempted to modulate NO signaling via chronic nitrate supplementation of the mdx mouse but failed to demonstrate beneficial modulation of key dystrophic features (i.e., metabolism). Instead, we observed increased muscle damage and nitrosative stress which exacerbated MD. Here, we highlight that acute nitrite treatment of human DMD myoblasts is also detrimental and suggest strategies for moving forward with NO replacement therapy in DMD.
doi:10.3390/antiox9121268 pmid:33322149 fatcat:oangqtehlrakvpy3fiyszd74jq